We detected a novel susceptibility gene, SLER1, for systemic lupus erythematosus (SLE) at 5p15.3.1 This finding was based on a selected subgroup of SLE families, where two or more family members ...

Recent advances in genotyping technology have identified or confirmed more than 20 loci that are associated with susceptibility to systemic lupus erythematosus (SLE). These findings add detail to ...

Systemic lupus erythematosus (SLE) is the most common type of lupus, a chronic autoimmune disease. Symptoms include fatigue, joint pain, and rashes across your nose and cheeks. While there’s no ...

In all evaluable patients, the SLE Response Index (SRI)-4 response rates at week 12 were 50.0% (7/14), 61.5% (8/13) and 64.3% (9/14) in patients treated with orelabrutinib at 50mg, 80mg and 100mg ...

The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus (SLE) with extrarenal involvement. The FDA’s ...

The median follow-up was 15 months (range, 4 to 29). The mean (±SD) duration of B-cell aplasia was 112±47 days. All the patients with SLE had DORIS remission, all the patients with idiopathic ...

However, they stress that non-pharmacological options should not replace drug therapy when it is required, and refer readers to the full management recommendations for SLE and SSc.

Using FATIGUE-PRO, a measure recently developed to capture the patient experience of fatigue in SLE, greater improvements from baseline (nominal* p<0.05) were observed in people receiving DZP ...

Systemic lupus erythematosus (SLE) is the most common form of lupus — it’s the type that 7 in 10 people with lupus have. It's what most people mean when they say "lupus." What causes SLE? Experts ...